Asset profile
SHR-1139
Monoclonal antibody
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Ulcerative Colitis · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
131 competitors in this universe: 16 direct rivals (same mechanism and indication), 0 same-class, 115 same-indication; 104 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| SHR-1139: this drug | Phase 2 | Monoclonal antibody | IL-23 p19, IL-36 receptor | ||
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Mirikizumab (Omvoh) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Risankizumab (Skyrizi) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Spesolimab (Spevigo (approved elsewhere, for GPP)) | Approved | Monoclonal antibody | IL-36 receptor | ||
| Tildrakizumab (Ilumya) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Ustekinumab-Stba (Steqeyma) | Approved | — | IL-23 p19, IL-12 p40 | ||
| Ustekinumab-Ttwe (Pyzchiva) | Approved | — | IL-23 p19, IL-12 p40 | ||
| HS-20137 | Phase 3 | Monoclonal antibody | IL-23 p19 | ||
| JNJ-78934804 | Phase 3 | Combination | IL-23 p19, TNF-alpha | ||
| Picankibart | Phase 3 | Monoclonal antibody | IL-23 p19 | ||
| HB0034 | Phase 2/3 | Monoclonal antibody | IL-36 receptor | ||
| MT-201 | Phase 2 | Multispecific antibody | TL1A, IL-23 p19 | ||
| ORKA-001 | Phase 2 | Monoclonal antibody | IL-23 p19 | ||
| SPY003 | Phase 2 | Monoclonal antibody | IL-23 p19 | ||
| SOR102 | Phase 1 | Biologic (subtype unspecified) | TNF-alpha, IL-23 p19 |
…and 116 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
2027 (4)
June 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (1)
What to watch
December 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.